Claims for Patent: 11,266,635
✉ Email this page to a colleague
Summary for Patent: 11,266,635
Title: | Methods of treating gastrointestinal stromal tumors |
Abstract: | The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof. |
Inventor(s): | Soto; Rodrigo Ruiz (Waltham, MA), Rosen; Oliver (Waltham, MA), Pitman; Jama (Waltham, MA) |
Assignee: | Deciphera Pharmaceuticals, LLC (Waltham, MA) |
Application Number: | 17/180,218 |
Patent Claims: |
1. A method of treating a patient suffering from Grade 2 or Grade 3 palmer-planter erythrodysesthesia syndrome while being administered 150 mg ripretinib daily or
twice daily for treatment of gastrointestinal stromal tumors, comprising: withholding administration of ripretinib for at least 7 days or until the patient has less than or equal to Grade 1 palmer-plantar erythrodysesthesia syndrome then administering to
the patient 100 mg daily ripretinib for at least 28 days, if the patient is suffering from Grade 3 palmer-planter erythrodysesthesia syndrome; or if the patient is suffering from Grade 2 palmer-planter erythrodysesthesia syndrome, withholding
administration of ripretinib until the patient has less than or equal to Grade 1 palmer-plantar erythrodysesthesia syndrome or baseline; if the patient recovers from the palmer-plantar erythrodysesthesia syndrome within 7 days of withholding
administration, then administering to the patient 150 mg daily ripretinib, or if the patient has not recovered, then administering to the patient 100 mg daily ripretinib for at least 28 days.
2. The method of claim 1, wherein the patient suffers from the Grade 2 or Grade 3 palmer-plantar erythrodysesthesia syndrome while being administered 150 mg ripretinib daily. 3. The method of claim 1, wherein the patient suffers from the Grade 2 or Grade 3 palmer-plantar erythrodysesthesia syndrome while being administered 150 mg ripretinib twice daily. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.